Cargando…
Recurrent candidal intertrigo: challenges and solutions
Intertrigo is a common inflammatory dermatosis of opposing skin surfaces that can be caused by a variety of infectious agents, most notably candida, under the effect of mechanical and environmental factors. Symptoms such as pain and itching significantly decrease quality of life, leading to high mor...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909782/ https://www.ncbi.nlm.nih.gov/pubmed/29713190 http://dx.doi.org/10.2147/CCID.S127841 |
_version_ | 1783315957669691392 |
---|---|
author | Metin, Ahmet Dilek, Nursel Bilgili, Serap Gunes |
author_facet | Metin, Ahmet Dilek, Nursel Bilgili, Serap Gunes |
author_sort | Metin, Ahmet |
collection | PubMed |
description | Intertrigo is a common inflammatory dermatosis of opposing skin surfaces that can be caused by a variety of infectious agents, most notably candida, under the effect of mechanical and environmental factors. Symptoms such as pain and itching significantly decrease quality of life, leading to high morbidity. A multitude of predisposing factors, particularly obesity, diabetes mellitus, and immunosuppressive conditions facilitate both the occurrence and recurrence of the disease. The diagnosis of candidal intertrigo is usually based on clinical appearance. However, a range of laboratory studies from simple tests to advanced methods can be carried out to confirm the diagnosis. Such tests are especially useful in treatment-resistant or recurrent cases for establishing a differential diagnosis. The first and key step of management is identification and correction of predisposing factors. Patients should be encouraged to lose weight, followed up properly after endocrinologic treatment and intestinal colonization or periorificial infections should be medically managed, especially in recurrent and resistant cases. Medical treatment of candidal intertrigo usually requires topical administration of nystatin and azole group antifungals. In this context, it is also possible to use magistral remedies safely and effectively. In case of predisposing immunosuppressive conditions or generalized infections, novel systemic agents with higher potency may be required. |
format | Online Article Text |
id | pubmed-5909782 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-59097822018-04-30 Recurrent candidal intertrigo: challenges and solutions Metin, Ahmet Dilek, Nursel Bilgili, Serap Gunes Clin Cosmet Investig Dermatol Review Intertrigo is a common inflammatory dermatosis of opposing skin surfaces that can be caused by a variety of infectious agents, most notably candida, under the effect of mechanical and environmental factors. Symptoms such as pain and itching significantly decrease quality of life, leading to high morbidity. A multitude of predisposing factors, particularly obesity, diabetes mellitus, and immunosuppressive conditions facilitate both the occurrence and recurrence of the disease. The diagnosis of candidal intertrigo is usually based on clinical appearance. However, a range of laboratory studies from simple tests to advanced methods can be carried out to confirm the diagnosis. Such tests are especially useful in treatment-resistant or recurrent cases for establishing a differential diagnosis. The first and key step of management is identification and correction of predisposing factors. Patients should be encouraged to lose weight, followed up properly after endocrinologic treatment and intestinal colonization or periorificial infections should be medically managed, especially in recurrent and resistant cases. Medical treatment of candidal intertrigo usually requires topical administration of nystatin and azole group antifungals. In this context, it is also possible to use magistral remedies safely and effectively. In case of predisposing immunosuppressive conditions or generalized infections, novel systemic agents with higher potency may be required. Dove Medical Press 2018-04-17 /pmc/articles/PMC5909782/ /pubmed/29713190 http://dx.doi.org/10.2147/CCID.S127841 Text en © 2018 Metin et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Metin, Ahmet Dilek, Nursel Bilgili, Serap Gunes Recurrent candidal intertrigo: challenges and solutions |
title | Recurrent candidal intertrigo: challenges and solutions |
title_full | Recurrent candidal intertrigo: challenges and solutions |
title_fullStr | Recurrent candidal intertrigo: challenges and solutions |
title_full_unstemmed | Recurrent candidal intertrigo: challenges and solutions |
title_short | Recurrent candidal intertrigo: challenges and solutions |
title_sort | recurrent candidal intertrigo: challenges and solutions |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909782/ https://www.ncbi.nlm.nih.gov/pubmed/29713190 http://dx.doi.org/10.2147/CCID.S127841 |
work_keys_str_mv | AT metinahmet recurrentcandidalintertrigochallengesandsolutions AT dileknursel recurrentcandidalintertrigochallengesandsolutions AT bilgiliserapgunes recurrentcandidalintertrigochallengesandsolutions |